This site is intended for healthcare professionals. Not a healthcare professional? Visit Mill-Klinika

New Tresiba® Summary of Product Characteristics: European Commission approves the label expansion to include children with type 1 and type 2 diabetes

In December 2014 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for expanded use of Tresiba® (insulin degludec) in children and adolescents aged 1-17 years with diabetes. And now, after the approval of the European…

Tresiba (Insulin Degludec): Flexibility in day-to-day dosing time when needed

Poor glucose control in patients with diabetes can ultimately result in diabetic complications that can bedevastating for the patient’s quality of life, life-shortening, and expensive to treat for national healthcare systems.Current expert guidelines on the treatment of type 2 diabetes therefore advocate the addition of…